MARKET WIREYahoo Finance • 8h ago
Why Krystal Biotech (KRYS) Is Drawing Fresh AttentionYahoo Finance report covering Krystal Biotech Inc. (KRYS) market action, institutional positioning, and fundamental catalysts.
Why KRYS Stock surged +2.38% Today — RQD Quant Desk Flash
$332.29 +2.38% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $334.51
Krystal Biotech Inc. (KRYS) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (steady margins, 17% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
ROARABLE B • BUY
Cap $9.61B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on KRYS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is KRYS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Krystal Biotech Inc. (NASDAQ: KRYS) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $332.29 (+2.38% 1D, market cap $9.61B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, KRYS ranks #68 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does KRYS compare to PCVX and IBRX in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), KRYS carries a Roarable B (72/100 RQD), trailing P/E of 46.9x, gross margin of —, and ROIC of 16.5%. By comparison, PCVX (Vaxcyte Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -27.6%, cap $9.85B) and IBRX (ImmunityBio Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -27.3%, cap $9.26B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for KRYS?
▼
Per KRYS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001711279), Krystal Biotech Inc. generated $389.1M in revenue (+33.9% YoY), $204.8M in net income, and $188.9M in free cash flow against $1.33B in total assets and $51.4M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 47x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $334.52 (+0.67%)🧬 Disciplined Float (-0.04% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 48.5% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERBUY • B
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw C · Rk A-
Each axis scored 0–20
12M PRICE TARGET CONE+6.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KRYS)Realized 20D OHLCV Swing Band: ±6.1%
Deterministic 5-Pillar Attribution (72/100 Composite)
🔍 WHY KRYS SCORES 72/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)
Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9
▲ #2 Bullish Driver: Cash Engine Quality+17/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 48.5% FCF Margin ($188.9M FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning10/20 pts (-10 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-10 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C+$321.16+1.3% Next Q
64
Q2 (-2Q)Grade B-$325.42-1.5% Next Q
67
Q3 (-1Q)Grade B-$320.58+3.7% Next Q
69
CurrentGrade B$332.29+7% Hist 90D α
72
Trajectory: C+ (64) → B (72)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER
⚔️ Adversarial Opposing Case: Why the KRYS Bull Thesis Could Fail
Even with a 72/100 (B) score, KRYS faces multiple-compression risk if 46.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
⚠️ Forensic Kill-Switch #1
Priced at 47x earnings—high expectations leave less room for a lukewarm quarter.
⚠️ Forensic Kill-Switch #2
Dilution & Margin Drag: Disciplined Float (-0.04% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
⚠️ Forensic Kill-Switch #3
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($336.68) or 200D SMA ($308.94) invalidates the momentum regime and cuts Target Base ($353.22) toward Bear Floor ($272.48).
🎲 LIVE PREDICTION MARKET ODDS TIED TO $KRYS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KRYS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why KRYS Stock surged +2.38% Today — RQD Quant Desk Flash
Krystal Biotech Inc. (KRYS) surged +2.38% to $332.29, trading at 75% of its 52-week range ($184.02 – $382.54). High-quality cash engine (steady margins, 17% return on capital) with steady institutional support.
- ▸Technical Tape: Trading at 75% of its 52-week range ($184.02 – $382.54) with RSI-14 at 48.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±6.1% around $332.29 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable B (Buy) backed by 52% gross margin and $188.9M annual free cash flow.
Live KRYS Headlines & Catalysts
MARKET WIRETrefis • 11h ago
Has The Story Under Krystal Biotech Stock Run Out?Trefis report covering Krystal Biotech Inc. (KRYS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStockInvest.us • 14h ago
Krystal Biotech Stock Price Forecast. Should You Buy KRYS?StockInvest.us report covering Krystal Biotech Inc. (KRYS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 17h ago
Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value (NASDAQ:KRYS)Seeking Alpha report covering Krystal Biotech Inc. (KRYS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 20h ago
Krystal Biotech, Inc. Estimates – NASDAQ:KRYSTradingView report covering Krystal Biotech Inc. (KRYS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance UK • 23h ago
Krystal Biotech (KRYS) Stock Looks Overvalued After A 7x RunYahoo Finance UK report covering Krystal Biotech Inc. (KRYS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much TodayBenzinga report covering Krystal Biotech Inc. (KRYS) market action, institutional positioning, and fundamental catalysts.
MARKET WIRE富途牛牛 • 1d ago
Insiders At Krystal Biotech Sold US$54m In Stock, Alluding To Potential Weakness富途牛牛 report covering Krystal Biotech Inc. (KRYS) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 12h ago
Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch VYJUVEK pricing negotiations in Germany and Italy completed KB113 clinical data demonstrate regression in more than 80% of assessed basal cell car
MARKET WIREBenzinga • 13h ago
Krystal Biotech Q3 2026 Earnings Call TranscriptKrystal Biotech (NASDAQ:KRYS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by Benzinga APIs.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk
Scheduled RQD Strong Buys & Whale Accumulation Briefing (KRYS Tape Review)
- ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
- ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
- ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
KRYS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +15.80%📐 WEDGE COMPRESSION COIL
2026-11-02O $321.4H $332.3L $321.4C $332.3VOL 190.9K
RES: $364.9SUP: $310.9SMA50: $336.7SMA200: $308.9
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
KRYS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
34.6%/yr Implied 5Y Growth
vs. +33.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on KRYS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for KRYS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KRYS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KRYS)
Health Care Rank #68 of 1016
⚔️ PCVX vs KRYS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (KRYS vs. PCVX, IBRX, KYMR, QGEN)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Krystal Biotech Inc. (KRYS) ranks #68 by composite RQD confidence (72/100, grade B) and #117 by equity capitalization ($9.61B). Within this direct 5-issuer industry benchmark cohort, QGEN leads on earnings valuation at 24.4x trailing P/E, while KRYS leads on capital efficiency and profitability with 16.5% ROIC and — gross margin. KRYS currently leads its immediate peer cohort in composite quantitative strength at 72/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| KRYS
ACTIVE
Krystal Biotech Inc. | B | 72/100 | 46.9x | — | 16.5% | +2.38% | $9.61B | Benchmark Subject |
| PCVX Vaxcyte Inc. | D | 49/100 | — | — | -27.6% | -0.93% | $9.85B | /pcvx-vs-krys → |
| IBRX ImmunityBio Inc. | D- | 37/100 | — | 96.0% | -27.3% | -5.15% | $9.26B | /ibrx-vs-krys → |
| KYMR Kymera Therapeutics Inc. | D | 50/100 | 32.7x | — | -21.4% | +3.29% | $10.19B | /kymr-vs-krys → |
| QGEN Qiagen N.V. | B- | 71/100 | 24.4x | 62.2% | 8.0% | -0.24% | $10.37B | /qgen-vs-krys → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001711279In its most recent audited fiscal period (FY2025, filed 2025-12-31), Krystal Biotech Inc. (KRYS) reported GAAP revenue of $389.1M (+33.9% vs. FY2024 revenue of $290.5M , and +667.5% cumulative change since FY2023) , GAAP net income of $204.8M, operating cash flow of $200.9M, and free cash flow of $188.9M (+58.5% YoY). On the balance sheet, KRYS closed FY2025 with $1.33B in total assets against $51.4M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 8/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $389.1M | $204.8M | $200.9M | $188.9M | $1.33B | $51.4M |
| FY2024 (FY) | 2024-12-31 | $290.5M | $89.2M | $123.4M | $119.2M | $1.06B | $49.3M |
| FY2023 (FY) | 2023-12-31 | $50.7M | $10.9M | -$88.8M | -$91.1M | $5.28B | $1.24B |
3. KRYS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs KRYS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Krystal Biotech Inc. (NASDAQ: KRYS) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $332.29 (+2.38% 1D, market cap $9.61B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, KRYS ranks #68 in composite RQD confidence.
How does KRYS compare to PCVX and IBRX in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), KRYS carries a Roarable B (72/100 RQD), trailing P/E of 46.9x, gross margin of —, and ROIC of 16.5%. By comparison, PCVX (Vaxcyte Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -27.6%, cap $9.85B) and IBRX (ImmunityBio Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -27.3%, cap $9.26B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for KRYS?
Per KRYS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001711279), Krystal Biotech Inc. generated $389.1M in revenue (+33.9% YoY), $204.8M in net income, and $188.9M in free cash flow against $1.33B in total assets and $51.4M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 47x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is KRYS trading relative to its 50-day, 200-day, and 52-week technical levels?
KRYS last traded at $332.29 (+2.38% on volume of 330,472 shares), positioning the stock -1.30% below its 50-day simple moving average ($336.68) and +7.56% above its 200-day simple moving average ($308.94). Across its 52-week range of $184.02 to $382.54, KRYS sits at the 74.7% percentile with a 14-day RSI of 48.2 (NEUTRAL RANGE) and an implied next-earnings move of ±6.1% ($312.02 to $352.56).
KRYS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is KRYS stock moving today?
Why KRYS Stock surged +2.38% Today — RQD Quant Desk Flash. High-quality cash engine (steady margins, 17% return on capital) with steady institutional support.
ROARABLE RATING BRIEF • RQD 72/100 (B)
✓ STAGE-C NUMBER FIREWALL VERIFIED
KRYS — Krystal Biotech Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:16:54Z
Roarable Rating Brief: What This Means to a Prospective Investor
The per the Roarable RQD rating, KRYS scores 72 out of 100, grading B, with the verdict "Roarable Buy — Good Risk/Reward." The five pillars are:
- Fundamental Cash Engine: 17 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 16.5% and an FCF yield of 1.97%. For an investor, this is the strongest evidence that the business converts capital into returns, though the low FCF yield means the market is paying a high price for each dollar of free cash flow.
- Whale 13F Flow: 10 / 20. Per the Roarable RQD rating, this pillar captures institutional accumulation and options positioning. The moderate score suggests institutional support is present but not dominant; no 13F detail is provided beyond the score.
- Insider Conviction: 12 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. A mid-range score indicates insider signals are neither a strong endorsement nor a warning.
- Macro Regime Fit: 15 / 20. Per the Roarable RQD rating, this pillar reflects beta of 0.91 and sector sensitivity. A beta below 1 implies the stock has historically moved less than the market, a defensive trait that benefits investors in volatile regimes but may lag in strong rallies.
- Forensic Balance Sheet: 18 / 20. Per the Roarable RQD rating, this pillar reflects Altman Z of 26, Piotroski F of 8/9, and Debt/Equity of 0.04. This is the strongest pillar and indicates low financial distress risk.
Valuation tradeoff: per the market data, the stock trades at a trailing P/E of 46.9 and an EV/EBITDA of 53.4, which the Roarable RQD rating does not separately penalize within its five pillars. An investor should weigh the strong forensic and cash-generation scores against the premium multiples and the 1.97% FCF yield when evaluating the stock today. This is an analytical framing, not personalized advice.
Snapshot
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $389.1M | $161.3M | $204.8M | N/A | $188.9M | $496.3M | $51.4M |
| FY 2024 | $290.5M | $65.7M | $89.2M | N/A | $119.2M | $344.9M | $49.3M |
| FY 2023 | $50.7M | $-109.6M | $10.9M | N/A | $-91.1M | N/A | $1236.3M |
Per the SEC financials, revenue rose from $50.7M in FY 2023 to $389.1M in FY 2025, and operating income moved from $-109.6M to $161.3M over the same span. Per the market data, the operating margin is 41.5% and the net margin is 52.6%, with ROIC at 16.5%. Per the Roarable RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 8/9. Per the SEC financials, debt fell from $1236.3M in FY 2023 to $51.4M in FY 2025, and the RQD rating reports Debt/Equity of 0.04. Gross margin is reported as 0% in the market data and should be treated as unreliable without further context.
Open Questions
- What are the company's specific products, approved indications, and revenue concentration, given the profile provides only sector and industry labels?
- What drove the move from $50.7M revenue in FY 2023 to $389.1M in FY 2025, and is that growth sustainable?
- Why is gross margin reported as 0%, and what is the true cost structure?
- Which institutions hold KRYS, and how have their positions changed over time?
- How do analysts value the stock relative to a 46.9 trailing P/E and 53.4 EV/EBITDA?
KRYS Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Krystal Biotech Inc. (KRYS) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 8h ago
Why Krystal Biotech (KRYS) Is Drawing Fresh Attention Yahoo Finance report covering Krystal Biotech Inc. (KRYS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Trefis • 11h ago
Has The Story Under Krystal Biotech Stock Run Out? Trefis report covering Krystal Biotech Inc. (KRYS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE StockInvest.us • 14h ago
Krystal Biotech Stock Price Forecast. Should You Buy KRYS? StockInvest.us report covering Krystal Biotech Inc. (KRYS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 17h ago
Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak Value (NASDAQ:KRYS) Seeking Alpha report covering Krystal Biotech Inc. (KRYS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 20h ago
Krystal Biotech, Inc. Estimates – NASDAQ:KRYS TradingView report covering Krystal Biotech Inc. (KRYS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance UK • 23h ago
Krystal Biotech (KRYS) Stock Looks Overvalued After A 7x Run Yahoo Finance UK report covering Krystal Biotech Inc. (KRYS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
$1000 Invested In Krystal Biotech 5 Years Ago Would Be Worth This Much Today Benzinga report covering Krystal Biotech Inc. (KRYS) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE 富途牛牛 • 1d ago
Insiders At Krystal Biotech Sold US$54m In Stock, Alluding To Potential Weakness 富途牛牛 report covering Krystal Biotech Inc. (KRYS) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
KRYS Bull vs. Bear Conversation Board — What's Your Call at $332.29?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KRYS 🐻 33% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH
🎯 Target: $382.97 (+18.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is KRYS (B • RQD 72/100) a Buy at $324.55?
Welcome to the KRYS (Krystal Biotech Inc.) Roar Pit. Current RQD Composite is 72/100 (Roarable Buy — Good Risk/Reward) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to capital efficiency (16.5% ROIC), while bears focus on valuation multiple compression (46.9x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $272.62 (-16.0%)
Spot @ $324.55 Pump the brakes on KRYS — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on KRYS, but look at what you are paying: 46.9x trailing P/E with tightening sector spreads. Unless Krystal Biotech Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH
🎯 Target: $386.21 (+19.0%)
Spot @ $324.55 KRYS cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on KRYS, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $324.55 (52-wk range $184.02 - $382.54), any beat on forward guidance forces shorts and underweight funds to chase.